Share This:
https://ntp.niehs.nih.gov/go/13775

Target Organs and Levels of Evidence for TR-350

Toxicology and Carcinogenesis Studies of Tribromomethane (Bromoform) (CASRN 75-25-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review DatePrimary UsesRoute/Exposure LevelsStudy Laboratory
Tribromomethane
75-25-2
04/18/1988Synthesis of pharmaceuticals, in shipbuilding, aircraft industry, in fire-resistant chemicals, sedative medication, antitussive, antiseptic (HSDB 1990)Gavage
R&FM: 0,100,200, MM: 0,50,100 MG/KG/50 PER GROUP
T.S.I. Mason Laboratories, Inc.

Levels of Evidence

Male Rats: Some Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Large Intestines: ADENOMATOUS POLYP 0/50 0/50 2/50 OR ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50
Non-Neoplastic Lesions
  • LIVER: FATTY CHANGE 23/50 49/50 50/50; INFLAMMATION, CHRONIC ACTIVE 0/50 29/50 23/50; NECROSIS 7/50 3/50 20/50
Female Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Large Intestines: ADENOMATOUS POLYP 0/48 1/50 6/49 OR ADENOCARCINOMA 0/48 0/50 2/49 COMBINED 0/48 1/50 8/49
Non-Neoplastic Lesions
  • LIVER: FATTY CHANGE 19/50 39/49 46/50; INFLAMMATION, CHRONIC ACTIVE 9/50 8/49 27/50; MIXED CELL FOCUS 8/50 25/49 28/50
Male Mice: No Evidence
Female Mice: No Evidence